Search

Displaying results 2381 - 2390 of 10000 in total
  1. Target

    Cytochrome b6-f complex iron-sulfur subunit

    go.drugbank.com/bio_entities/BE0002474
    TargetMastigocladus laminosus

    Component of the cytochrome b6-f complex, which mediates electron transfer between photosystem II (PSII) and photosystem I (PSI), cyclic electron flow around PSI, and state transitions.

    Polypeptides: Cytochrome b6-f complex iron-sulfur subunit
  2. Target

    Cytochrome b-c1 complex subunit Rieske, mitochondrial

    go.drugbank.com/bio_entities/BE0003858
    TargetHumans

    The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase … The Rieske protein is a catalytic core subunit containing a [2Fe-2S] iron-sulfur cluster.

    Polypeptides: Cytochrome b-c1 complex subunit Rieske, mitochondrialSynonyms: Complex III subunit 5, Cytochrome b-c1 complex subunit 5
  3. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    in Pompe disease. … Compared to alglucosidase alfa, cipaglucosidase alfa has a higher M6P content.

  4. Drug

    Levomilnacipran

    go.drugbank.com/drugs/DB08918
    ApprovedInvestigational

    [L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.[L48011] … [L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults.

    Synonyms: CYCLOPROPANECARBOXAMIDE, 2-(AMINOMETHYL)-N,N-DIETHYL-1-PHENYL-, (1S,2R)-
  5. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    [A260641] Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although with a 10-fold lower affinity compared to wild-type FLT3. … with other targets in mind.

    Synonyms: N-(5-(1,1-Dimethylethyl)isoxazol-3-yl)-N'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)urea
  6. Target

    Major histocompatibility complex class I-related protein 1

    go.drugbank.com/bio_entities/BE0003573
    TargetHumans

    In complex with B2M preferentially presents riboflavin-derived metabolites to semi-invariant TRAV1.2 TCRs on MAIT cells, guiding immune surveillance of the microbial metabolome at mucosal epithelial barriers

    Polypeptides: Major histocompatibility complex class I-related protein 1
  7. Target

    ATP synthase F(1) complex subunit gamma, mitochondrial

    go.drugbank.com/bio_entities/BE0003842
    TargetHumans

    ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). … Subunit gamma, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated

    Polypeptides: ATP synthase F(1) complex subunit gamma, mitochondrial
  8. Target

    ATP synthase F(0) complex subunit e, mitochondrial

    go.drugbank.com/bio_entities/BE0009021
    TargetHumans

    Part of the complex F(0) domain (PubMed:37244256) … ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256).

    Polypeptides: ATP synthase F(0) complex subunit e, mitochondrialFunction: protein-containing complex binding
  9. Drug

    L-arginine

    go.drugbank.com/drugs/DB17289
    ApprovedInvestigationalNutraceutical

    Mixtures: Aminosyn II 7% M In 10% Dextrose(dual Chamber), Aminosyn II 8.5% M In 20% Dextrose (dual Chamber)
  10. Drug

    Viloxazine

    go.drugbank.com/drugs/DB09185
    ApprovedInvestigationalWithdrawn

    [L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. … In the US, viloxazine was assigned an orphan drug designation in 1984 under the brand name CATATROL: while this product was intended to treat cataplexy and narcolepsy, the drug was never approved for these